About Multiple Myeloma
Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight. The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.
TechNavio's analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Celgene
• Johnson & Johnson
• Novartis
• Onyx Pharmaceuticals
• Sanofi
• Takeda Pharmaceutical
Other Prominent Vendors
• AB Science
• Abbvie
• Aeterna Zentaris
• Amgen
• Bristol Myers Squibb
• Cephalon
• Daiichi Sankyo
• Genta
• Merck Sharp and Dohme
• Oncotherapeutics
• PharmaMar
• Teva
Market Driver
• Presence of Unmet Needs
• For a full, detailed list, view our report
Market Challenge
• High Cost of Treatment
• For a full, detailed list, view our report
Market Trend
• Growing Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Pomalyst/ Imnovid
04.1.2 Revlimid
04.1.3 Zometa
04.1.4 Doxil/Caelyx
04.1.5 Thalomid/ Thalidomide Celgene
04.1.6 Kyprolis
04.1.7 Mozobil
04.1.8 Velcade
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding Multiple Myeloma
07.2 Pathophysiology
07.3 Epidemiology
07.4 Diagnosis
07.5 Staging
07.6 Management
07.7 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10. Market Segmentation by Dosage Form
10.1 Solid
10.2 Liquid
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Pipeline Portfolio
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Celgene
20.2.2 Johnson & Johnson
20.2.3 Novartis
20.2.4 Onyx
20.2.5 Sanofi
20.2.6 Takeda Pharmaceutical
20.3 Other and Future Prominent Vendors
21. Key Vendor Analysis
21.1 Celgene
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Strategy
21.1.4 Business Segmentation by Revenue
21.1.5 Sales by Geography
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 Johnson & Johnson
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2013
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Geographical Segmentation by Revenue 2013
21.2.6 Business Strategy
21.2.7 Recent Developments
21.2.8 SWOT Analysis
21.3 Novartis
21.3.1 Key Facts
21.3.2 Business Description
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Sales by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis
21.4 Onyx Pharmaceuticals
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Marketed Products
21.4.4 Geographical Segmentation
21.4.5 Business Strategy
21.4.6 Recent Developments
21.4.7 SWOT Analysis
21.5 Sanofi
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Geographical Segmentation by Revenue 2013
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Takeda Pharmaceutical
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013
21.6.4 Business Segmentation by Revenue 2013
21.6.5 Geographical Segmentation by Revenue 2013
21.6.6 Business Strategy
21.6.7 Recent Developments
21.6.8 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Pathophysiology of Multiple Myeloma
Exhibit 3: Indicators of Multiple Myeloma
Exhibit 4: Laboratory Tests to Identify Multiple Myeloma
Exhibit 5: Diagnosis of Multiple Myeloma
Exhibit 6: Staging of Multiple Myeloma
Exhibit 7: Management of Multiple Myeloma
Exhibit 8: Induction Therapy Recommendations for the Transplant Eligible Candidates
Exhibit 9: Maintenance Therapy for the Candidates with Multiple Myeloma
Exhibit 10: Supportive Therapy for the Candidates with Multiple Myeloma
Exhibit 11: Estimated Expenditure for the Four Type of Treatment Regimens for Multiple Myeloma in the US
Exhibit 12: Snapshot of the Economic Burden of Multiple Myeloma
Exhibit 13: Snapshot of Global Multiple Myeloma Drugs Market 2014
Exhibit 14: Global Multiple Myeloma Drugs Market 2014-2019 (US$ million)
Exhibit 15: Global Multiple Myeloma Drugs Market Segmentation By Route Of Administration
Exhibit 16: Global Multiple Myeloma Drugs Market Segmentation by Route of Administration 2014
Exhibit 17: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form
Exhibit 18: Global Multiple Myeloma Drugs Market Segmentation by Dosage Form 2014
Exhibit 19: Global Multiple Myeloma Drugs Market by Geographical Segmentation 2014
Exhibit 20: Buying Criteria of Global Multiple Myeloma Drugs Market 2014
Exhibit 21: Growth Drivers of the Global Multiple Myeloma Drugs Market
Exhibit 22: Drivers and their Impact on the Key Customer Category of Global Multiple Myeloma Drugs Market 2014
Exhibit 23: Drivers and their Impact on the Geographies of Global Multiple Myeloma Drugs Market 2014
Exhibit 24: Challenges of the Global Multiple Myeloma Drugs Market
Exhibit 25: Trends of the Global Multiple Myeloma Drugs Market
Exhibit 26: Phase III Pipeline Molecules for Multiple Myeloma
Exhibit 27: Global Multiple Myeloma Drugs Market Share Analysis 2014
Exhibit 28: Sales Forecast of Pomalyst 2014-2018 (US$ million)
Exhibit 29: YoY Sales Comparison of Revlimid 2007-2013 (US$ million)
Exhibit 30: Sales Forecast of Revlimid 2014-2018 (US$ million)
Exhibit 31: YoY Sales Comparison of Thalomid 2007-2013 (US$ million)
Exhibit 32: Sales Forecast of Thalomid 2014-2018 (US$ million)
Exhibit 33: YoY Sales Comparison of Velcade outside the US 2008-2013 (US$ million)
Exhibit 34: Sales Comparison of Zometa in the US and ROW 2007-2013 (US$ million)
Exhibit 35: Global YoY Sales Comparison of Zometa 2007-2013 (US$ million)
Exhibit 36: YoY Sales Comparison of Zometa in the US 2007-2013 (US$ million)
Exhibit 37: YoY Sales Comparison of Zometa in ROW 2007-2013 (US$ million)
Exhibit 38: Sales Forecast of Kyprolis 2014-2018 (US$ million)
Exhibit 39: Global YoY Sales Comparison of Mozobil 2007-2013 (US$ million)
Exhibit 40: Global YoY Sales Comparison of Velcade in Japan 2009-2013 (US$ million)
Exhibit 41: Sales Forecast of Velcade 2014-2018 (US$ million)
Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 43: Celgene: Sales by Geography 2013
Exhibit 44: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 45: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 46: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 47: Novartis AG: Business Segmentation
Exhibit 48: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 49: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 50: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 51: Onyx Pharmaceuticals: Marketed Products
Exhibit 52: Onyx Pharmaceuticals: Geographical Segmentation
Exhibit 53: Sanofi: Business Segmentation by Revenue 2013
Exhibit 54: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 55: Sanofi: Geographical Segmentation by Revenue 2013
Exhibit 56: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 57: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 58: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
